HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex
复制标题
艾滋病和艾滋病相关复合物患者的 HTLV-III 中和抗体
作者：
M. Robert;Monica Brown;R. Gallo
从许多获得性免疫缺陷综合征（AIDS）患者的细胞中分离出人类T细胞白血病（嗜淋巴细胞）病毒III型（HTLV-III或淋巴结病相关病毒）1，2，首次证明该病毒是该疾病的病原体。随后的血清流行病学研究表明，在大多数艾滋病和艾滋病相关复合体（ARC）患者的血清中存在HTLV-III特异性抗体3，4，并且在许多有艾滋病风险的个体的血清中存在HTLV-III特异性抗体3 - 14。尽管有这些广泛的研究，但没有关于HTLV-III抗体保护作用的报道。相比之下，先前已经鉴定了对HTLV-I和HTLV-II具有特异性的中和抗体15。因此，我们研究了HTLV-III暴露个体是否具有能够抑制病毒感染的抗体活性（参见参考文献16、17）。在这里，我们报告，能够中和HTLV-III感染的H9细胞的天然抗体检测到大多数成年艾滋病和ARC患者，但没有正常的健康异性恋控制。ARC患者的几何平均抗体滴度是艾滋病患者的两倍，在两个抗体阳性的健康同性恋者中甚至更高。这表明病毒中和抗体可以发挥体内保护作用。这些抗体的存在表明对HTLV-III的免疫应答，其可能被操纵以获得治疗优势。这里使用的方法将有助于监测未来的疫苗方法。
The isolation of the human T-cell leukaemia (lymphotropic) virus type III (HTLV-III or lymphadenopathy-associated virus) from cells of many patients with acquired immune deficiency syndrome (AIDS)1,2 presented the first evidence that the virus was the aetio-logical agent of the disease. Subsequent seroepidemiological studies have shown the presence of HTLV-III-specific antibodies in the serum of most patients with AIDS and AIDS-related complex (ARC)3,4, and in the serum of many individuals at risk for AIDS3–14. Despite these extensive studies, there are no reports of protective effects of HTLV-III antibodies. In contrast, neutralizing antibodies specific for HTLV-I and -II have been identified previously15. Therefore, we investigated whether HTLV-III-exposed individuals possess antibody activities capable of inhibiting viral infection (see also refs 16, 17). Here, we report that natural antibodies capable of neutralizing HTLV-III infection of H9 cells were detected in most adult AIDS and ARC patients but in no normal healthy heterosexual controls. Geometric mean antibody titres in ARC patients were double those in AIDS patients, and were even higher in two antibody-positive healthy homosexuals. This suggests that virus neutralizing antibodies may exert an in vivo protective effect. The presence of these antibodies indicates an immunological response to HTLV-III which potentially may be manipulated for therapeutic advantage. The methodology used here will be useful in monitoring future vaccine approaches.
影响因子：
56.9
作者：
GONDA, MA;WONGSTAAL, F;GILDEN, RV
通讯作者：
GILDEN, RV